 CRANFORD, N.J., April 29, 2021 PRNewswire -- Citius Pharmaceuticals, Inc. Citius or the Company Nasdaq: CTXR, a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, today announced updates delivered during its third Mino-Lok Phase 3 trial-related webinar. 